We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tetraphase

News List

Melinta Announces Termination of Merger Agreement for Tetraphase americanpharmaceuticalreview
July 03, 2020
Melinta Therapeutics announced pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp.
FDA Approves Tetraphase's XERAVA contractpharma
August 29, 2018
Tetraphase Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval of XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI).
Tetraphase enters into agreement with Biopharma firm in China biospectrumasia
February 26, 2018
As per the agreement, Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million as well as annual sales milestones of up to $20.0 million.